biOOrg3.14

DIABETES: BG-319

Disease-Modifying Short Course Therapy For Diabetes Remission

biOOrg3.14 was founded in 2017 based on the discovery of BG-319, a novel molecule that lowers blood glucose.

Background

Two major gaps persist in diabetes care: 1) The lack of disease-modifying therapies: no approved drug reverses or substantially halts diabetes progression, most people require insulin within 10 years after diagnosis; and 2) only half of the 38 million Americans (500 million people globally) with diabetes achieve glycemic control.

These gaps contribute to diabetes complications, including myocardial infarction, stroke, kidney failure, blindness, and limb amputation.

Our Approach

BG-319 is an orally available small molecule that triggers muscle to take up glucose and convert it to glycogen via an insulin-independent mechanism, reducing circulating insulin, blood sugar, and insulin demand.

BG-319 targets two indications:

SHORT-COURSE THERAPY

To induce durable, drug-free glycemic control after 3 to 6 months of therapy. For people newly diagnosed type 2 diabetes, with an estimated 3-4 million in the U.S.

MANAGEMENT OF SEVERE INSULIN RESISTANCE

For glycemic control in individuals requiring >200 units of insulin daily, an estimated 80,000–300,000 people.

Potential Impact

BG-319 targets the $400 billion global market. If successful, BG-319 would transform diabetes care from lifelong therapy and drug dependence to a condition that is treatable with a short, finite treatment, while improving outcomes for people with severe cases of diabetes. BG-319 would simplify diabetes care and reduce long-term complications and associated health care costs.

Status

Preclinical.

biOOrg3.14 is seeking investment and strategic partnerships to accelerate clinical development of BG-319

APPENDIX

BACK TO ALL THERAPEUTIC PROGRAMS

ONCOLOGY
ANTI-PATHOGEN
RETINAL DISEASE

For more information about partnerships, licensing, and investment:

EMAIL US

FOUNDED IN 2017

SITEMAP
PRIVACY POLICY
TERMS OF USE